Memory decline in most patients in a pilot study appeared to be reversed after they received a new Alzheimer’s treatment developed by NeuroEM Therapeutics, a medical device company with ties to Connecticut.
For the study, eight patients — ages 63 and older with mild to moderate Alzheimer’s — were given two months of transcranial electromagnetic treatments. The treatments were administered in each patient’s home by a caregiver, using a device called the MemorEM, a cap that patients wear and which delivered electric and magnetic radio waves to their brain. Seven patients responded to the treatment and performed on cognitive tests at a level equivalent to their performance 12 months earlier.
In August, the results of the study were published by the peer-reviewed Journal of Alzheimer’s Disease. NeuroEM Therapeutics is planning a larger study to confirm these findings. The treatment was developed by Dr. Gary Arendash, chief executive of NeuroEM Therapeutics, and the study was conducted at the University of South Florida Health Byrd Alzheimer’s Institute.
But the company owes part of its success to Connecticut inventor Eric Knight. After reading about Arendash’s work in this area, Knight designed a version of the treatment cap used by NeuroEm and received a patent for his device, which is now one of several devices NeuroEM has access to and that will be used in future studies. Knight, who now serves as the NeuroEM’s adviser for marketing and technology, also helped raise hundreds of thousands of dollars in funding for the company from Connecticut investors. He says the publication of the results of the study was the “proudest moment of my professional life.” We wrote about Knight and NeuroEm in-depth in our January 2018 issue.